NCNA - NuCana plc

NasdaqGS - NasdaqGS Delayed price. Currency in USD
0.8500
+0.0499 (+6.24%)
At close: 03:55PM EDT
0.8500 0.00 (0.00%)
After hours: 07:54PM EDT
Stock chart is not supported by your current browser
Previous close0.8001
Open0.8900
Bid0.8751 x 1100
Ask0.9000 x 1000
Day's range0.8000 - 0.8999
52-week range0.5700 - 2.2400
Volume18,331
Avg. volume106,466
Market cap44.529M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.7500
Earnings date15 Aug 2023 - 21 Aug 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.33
  • Globe Newswire

    NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

    Multiple Important Data Readouts Remain on Track for 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, May 17, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2023 and provided an update on its broad clinical development program with its transformative ProTide therapeutics. As of March 31, 2023, NuCana had cash and cash equivalents of £31.0 million compared to £41.9 million at December 31,

  • Globe Newswire

    NuCana Announces Receipt of Nasdaq Notice

    EDINBURGH, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC ("Nasdaq") dated May 9, 2023, indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares (“ADSs”) for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5450(a)(1). The Notification Letter has no

  • Globe Newswire

    NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

    NUC-7738 Reduces Secreted Forms of PD-L1 Indicating Potential Synergy with Checkpoint Inhibitors NUC-7738 Decreases Glutaminase in vitro and in Cancer Tissue Demonstrating Potential for Anti-Cancer Activity in Highly Metabolic Tumors ORLANDO, Fla., April 14, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two posters to be presented at the American Association of Cancer Research (AACR) Annual Meeting being held from April 14-19, 2023. Title: NUC-7738 causes reduction of soluble and

  • Globe Newswire

    NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

    Multiple Important Data Readouts Expected in 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, April 04, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics. As of December 31, 2022, NuCana had cash and cash equivalents of £41.9 million compared to £50.8 million as of September 30

  • Globe Newswire

    Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not Valid

    Ruling Has No Impact on NuCana’s Anti-Cancer ProTide PatentsMUNICH, Germany, March 24, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a hearing on March 24, 2023, the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) issued an oral judgement that NuCana’s European Patent 2955190 (the “’190 patent”) is not valid. The TBA reversed the previous decisions of the EPO’s Examination Division which issued NuCana’s ‘190 patent and of the EPO’s O

  • Simply Wall St.

    We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • Globe Newswire

    NuCana to Participate in Two Upcoming Investor Conferences

    EDINBURGH, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming investor conferences. Event: Cowen’s 43rd Annual Healthcare Conference Presentation Date: Tuesday, March 7, 2023Presentation Time: 10:30 AM ET Event: Oppenheimer's 33rd Annual Healthcare Conference Presentation Date: Tuesday, March 14, 2023Presentation Time: 12:40 PM ET The pres

  • Globe Newswire

    NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

    EDINBURGH, United Kingdom, Jan. 23, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the matter is

  • Globe Newswire

    NuCana to Host Investor Meetings During the J.P. Morgan Healthcare Conference

    EDINBURGH, United Kingdom, Jan. 03, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings during the 41st Annual J.P. Morgan Healthcare Conference, January 9 – 12, 2023 in San Francisco. About NuCanaNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleo

  • Zacks

    NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?

    NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Globe Newswire

    NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

    Multiple Data Readouts on Track for the Remainder of 2022 and the First Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, Nov. 16, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics. As of September 30, 2022, NuCana had cash and cash equivalents of £50.8 million compared to £46.5

  • Globe Newswire

    NuCana to Present at the Jefferies London Healthcare Conference

    EDINBURGH, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies London Healthcare Conference. Event: Jefferies London Healthcare ConferenceDates: Wednesday, November 16, 2022Time: 2:40 PM GMTLocation: London, UK The presentation will be webcast live and available for replay under “Events & Presentations” in the Inve

  • Globe Newswire

    NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

    NUC-3373 Potentiates Immunogenic Activity in Lung Cancer Cells Pembrolizumab Activity Increased by NUC-3373 in Lung Cancer Cells NuCana has Initiated the NuTide:303 Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel BARCELONA, Spain, Oct. 26, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced non-clinical data from two poster presentations at the 34th EORTC-NCI-AACR Annual Meeting being held from October 26 to 28, 2022. Abstract 185: NUC-3373 is a potent TS inhibitor and

  • Simply Wall St.

    Is NuCana (NASDAQ:NCNA) In A Good Position To Deliver On Growth Plans?

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • Zacks

    Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks

    NuCana PLC Sponsored ADR (NCNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

  • Zacks

    Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)

    The heavy selling pressure might have exhausted for NuCana PLC Sponsored ADR (NCNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

  • Globe Newswire

    NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

    NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors NUC-7738 Monotherapy and Combination with Pembrolizumab to be Investigated in Phase 2 PARIS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data today from the ongoing NuTide:701 study of NUC-7738 in an oral presentation at the European Society for Medical Oncology (ESMO) Annual Meeting. Oral 455MO: NUC-7738 in Patients with Advanced Solid Tumors- Phase 1

  • Globe Newswire

    NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

    NUC-3373 Demonstrates Promising Anti-Tumor Activity and Safety in Combination with Oxaliplatin (NUFOX) and Irinotecan (NUFIRI) in Heavily Pre-Treated Colorectal Cancer Patients Randomized Study of NUFIRI vs. FOLFIRI in Second-Line Colorectal Cancer Patients Initiated PARIS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data from the ongoing NuTide:302 study of NUC-3373 in combination with other agents at the European Society for Medical Oncology (ESMO) Annual Meeting bei

  • Globe Newswire

    NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

    EDINBURGH, United Kingdom, Sept. 06, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2022 being held September 9-13, 2022 at the Paris Expo Porte de Versailles in Paris, France. The details of NuCana’s presentations at ESMO are as follows: Title: NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuT

  • Globe Newswire

    NuCana to Participate in Citi's 17th Annual BioPharma Conference

    EDINBURGH, United Kingdom, Aug. 31, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings at Citi's 17th Annual BioPharma Conference. Event: Citi's 17th Annual BioPharma ConferenceDates: September 6-8, 2022Location: Boston, MA About NuCanaNuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widel

  • Globe Newswire

    NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

    Multiple Data Readouts on Track for the Second Half of 2022 and the First Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, Aug. 17, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics. As of June 30, 2022, NuCana had cash and cash equivalents of £46.5 million compared to £52.6 million

  • Simply Wall St.

    Here's What NuCana plc's (NASDAQ:NCNA) Shareholder Ownership Structure Looks Like

    Every investor in NuCana plc ( NASDAQ:NCNA ) should be aware of the most powerful shareholder groups. Institutions will...

  • Globe Newswire

    German Court Rules that Gilead’s Sofosbuvir Infringes NuCana’s ‘190 Patent

    EDINBURGH, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022, the Regional Court of Dusseldorf (the “Court”) issued a judgement on July 7, 2022 that Gilead Sciences Ireland UC and Gilead Sciences GmbH (together, “Gilead”) infringe NuCana’s composition of matter claims in European Patent 2955190 (the “’190 patent”) through their sales of Sovaldi®, Harvoni®, Vosevi® and Epclusa® in Germany. This judgement f

  • Globe Newswire

    NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

    NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates Potential Clinical Utility Beyond Solid Tumors EDINBURGH, United Kingdom, June 10, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data to be presented at the European Hematology Association (EHA) 2022 Hybrid Congress highlighting the activity of NUC-7738, a phosphoramidate transformation of 3’-deoxyadenosine (3’-dA), in a broad range of

  • Globe Newswire

    NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

    Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer Initiated Phase 1b/2 Study of NUC-3373 in Combination with Other Agents, Including PD-1 Inhibitors, in Patients with Solid Tumors First Patients Enrolled in Phase 2 Study of NUC-7738 Multiple Data Readouts in 2022 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, June 02, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March